Results
Tirzepatide Results and Timeline
Tirzepatide results accumulate over months rather than weeks, because dosing escalates gradually from 2.5 mg and trial weight curves continued falling through 72 weeks. Appetite changes are often noticed early, but the trial means quoted in marketing — about 20.9% at 15 mg — describe 72 weeks of treatment at a maintained dose, not an early result.
Key takeaways
- Trial results describe 72 weeks of treatment, not an early snapshot.
- Dosing escalates gradually from 2.5 mg, so the full dose is reached over months.
- Appetite change is often noticed within weeks, before meaningful weight change.
- Weight curves in SURMOUNT-1 continued falling through week 72 rather than plateauing early.
- Judging the drug at four or eight weeks is premature and a common source of disappointment.
| Trial duration | 72 weeks in SURMOUNT-1, -2, -3, and -5 |
|---|---|
| Starting dose | 2.5 mg weekly, per labelling |
| Maximum labelled dose | 15 mg weekly |
| Mean result at 15 mg | About 20.9% (SURMOUNT-1) |
| Curve shape | Continued decline through week 72 |
| Early signal | Appetite change often precedes weight change |
How soon should you expect to see anything?
Many people report reduced appetite and earlier fullness within the first few weeks, often before the scale moves much. That is consistent with the mechanism: the drug changes intake signalling immediately, while weight responds to accumulated energy balance over time.
Because escalation is gradual, the early weeks are spent at doses below those that produced the headline trial results.
Why do trial curves keep falling for 72 weeks?
Because the dose keeps rising for the first months and the effect on intake persists once maintenance is reached. Unlike diet interventions, where compliance typically decays and curves flatten or reverse by six months, the SURMOUNT curves continued downward through the end of the trial period.
This has a practical consequence: an assessment made at three months underestimates what the same person would have reached at twelve.
What explains the wide variation between individuals?
Trial means conceal substantial spread. Baseline weight, presence of type 2 diabetes, tolerated dose, adherence, and concurrent medication all shift the result, and some of the variation is simply unexplained biology. A person achieving 10% and a person achieving 25% can both be ordinary outcomes of the same prescription.
What the evidence shows
- Weight reduction accumulating over 72 weeks in randomised trials.
- Dose-dependent effect within the studied range.
What the evidence does not show
- A guaranteed personal timeline or result.
- That early non-response predicts final outcome.
Related: Tirzepatide for weight loss · How long it takes
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 56 | Wk 72 |
|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | 0% | -6.5% | -12.4% | -16.8% | -19.3% | -20.9% |
| Tirzepatide 5 mg | 0% | -5.1% | -9.3% | -12.4% | -14.2% | -15.0% |
| Placebo | 0% | -1.4% | -2.3% | -2.8% | -3.0% | -3.1% |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does the shape of the weight curve tell you?
The SURMOUNT-1 curves descend steeply for the first several months, then continue descending more gradually without flattening entirely by week 72. That shape is unusual among weight interventions. Diet trials typically show a nadir around six months followed by partial regain as adherence decays, producing a characteristic U-shape.
The absence of that reversal in the drug arms is one of the more important findings, and it has a practical implication that is easy to miss: a person assessing their result at three or six months is reading a point on a curve that is still moving. Trial-comparable results require trial-comparable duration.
Why do individual results vary so widely around the mean?
A mean of 20.9% conceals a distribution in which a substantial minority exceeded 25% and others achieved considerably less. Identified contributors include diabetes status, dose reached, adherence, and concurrent medication. Much of the remaining variation is simply not explained by anything currently measurable.
This has a consequence for how a person should interpret their own trajectory. An individual result below the mean is not evidence of doing something wrong, and an individual result above it is not evidence of doing something right. Both are ordinary outcomes of the same prescription in different bodies.
What does this page cover, and what does it deliberately leave out?
This page addresses Trial timelines, titration, weight and glucose outcomes and variability, organised around the primary question of tirzepatide results. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Trial timelines | Covered on this page | Primary evidence |
| Titration | Covered on this page | Primary evidence |
| Weight and glucose outcomes | Covered on this page | Primary evidence |
| Variability | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on tirzepatide results.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 4 technical terms this page uses, including DOI, adherence, placebo, titration — in the specific sense used above.
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
|---|---|
| adherence | The extent to which a person takes a medicine as prescribed. Real-world adherence to incretin therapy is considerably lower than in trials, which is a principal reason real-world weight outcomes are smaller. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| titration | The process of adjusting a drug dose over time, usually upward from a starting dose, to balance effect against tolerability. Tirzepatide titration is directed by a prescriber and is never published as a personal schedule on this site. |
Frequently asked questions
How long until tirzepatide works?
Appetite changes are often noticed within weeks; meaningful weight change accumulates over months as the dose escalates.
When will I reach my full result?
Trial curves continued falling through 72 weeks, so assessments at three months underestimate the eventual outcome.
Is it normal to lose slowly at first?
Yes — early weeks are spent at starting doses below those that produced the headline trial results.
Why do results vary so much between people?
Baseline weight, diabetes status, tolerated dose, adherence, and unexplained biological variation all contribute.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.